Kimberly Y. Smith

MedicineImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 4 papers. Top paper: “Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women”.

Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women

New England Journal of Medicine(2021)10.1056/nejmoa2101016

N/A

8.3DataRank · unranked

869 citations

Deborah Donnell, Meredith E. Clement, Brett Hanscom, Leslie Cottle, Lara E. Coelho +60 more

Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial

The Lancet(2022)10.1016/s0140-6736(22)00538-4

N/A

7.4DataRank · unranked

552 citations

James P. Hughes, Peter Bock, Samuel Gurrion Ouma, Portia Hunidzarira, Dishiki Kalonji +95 more

Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment–Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials

JAIDS Journal of Acquired Immune Deficiency Syndromes(2020)10.1097/qai.0000000000002275

N/A

0.806DataRank · unranked

214 citations

Juan Sierra Madero, José R. Arribas, Andrea Antinori, Roberto Ortiz, Amanda E. Clarke +16 more

Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority Study

Clinical Infectious Diseases(2023)10.1093/cid/ciad020

N/A

0DataRank · unranked

128 citations

Gary Richmond, Giuliano Rizzardini, Anders Thalme, Pierre‐Marie Girard, Alexander Wong +20 more